The B.C.-based company says it filed for CCAA to address near-term liquidity issues which were in “large part” caused by Health Canada’s suspension of its licences under its subsidiary Agrima Botanicals Corp.
Ascent has said that Health Canada asserts that “unauthorized activities” with cannabis took place during a period of time that it was privately held, and has suspended its producer and dealer’s licence under the former Access to Cannabis for Medical Purposes Regulations regime. Last month, Ascent said that Health Canada indicated that the company did not demonstrate that the suspension was not warranted and the government health agency still intends to revoke its licences, but it had until Feb. 20 to make additional submissions.Ascent said today that the suspension was negatively impacting its ability to complete its strategic review to address short-term liquidity issues.
The company added that while under CCAA protection, Ascent will continue with its day to day operations and the proceedings do not include or impact the operations and activities of its other subsidiaries, including in Oregon, Nevada and Denmark.